+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sickle Cell Disease Treatment Market by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy), Patient Age Group (Adult, Pediatric), Drug Administration Method, Disease Type, End User - Global Forecast 2025-2030- Product Image
Sickle Cell Disease Treatment Market by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy), Patient Age Group (Adult, Pediatric), Drug Administration Method, Disease Type, End User - Global Forecast 2025-2030- Product Image
Sale

Sickle Cell Disease Treatment Market by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy), Patient Age Group (Adult, Pediatric), Drug Administration Method, Disease Type, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6024723
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sickle Cell Disease Treatment Market grew from USD 3.25 billion in 2024 to USD 3.74 billion in 2025. It is expected to continue growing at a CAGR of 15.77%, reaching USD 7.84 billion by 2030.

Sickle Cell Disease (SCD) remains one of the most challenging hematological disorders affecting millions globally. Over the past decade, tremendous scientific progress and shifting clinical paradigms have ushered in a new era of therapeutic innovations. In this ever‐evolving landscape, established treatment regimens are being complemented by cutting‐edge interventions that target the disease at its molecular roots, aiming to improve patient quality of life and overall treatment outcomes.

Recent advances have led to a deeper understanding of the disease mechanism, inspiring therapeutic approaches that combine traditional methods with next‐generation treatments. Standard practices, such as blood transfusions and bone marrow transplants, are being reinvented, with clinicians now integrating novel pharmacotherapy options. These advancements not only signal a turning point in clinical management but also substantiate the commitment across the healthcare spectrum to address a condition that has long been associated with significant morbidity.

Innovation in treatment strategies is increasingly driven by collaborative efforts between clinicians, researchers, and biotechnology firms. This comprehensive overview explores market dynamics, transformative technological shifts, and emerging segmentation insights within the SCD treatment sector. As the clinical community pushes the boundaries of what is possible, the drive for personalized medicine and targeted interventions is paving a sustainable path for future care. The discussion that follows offers a detailed exploration of critical market trends and therapeutic strategies that are set to redefine the conventional approaches to Sickle Cell Disease management.

Transformative Shifts Redefining the Sickle Cell Treatment Paradigm

The Sickle Cell Disease treatment landscape is currently witnessing transformative shifts that promise to reshape clinical practice and significantly enhance patient outcomes. Traditional treatment modalities, once seen as static and uniform, are now undergoing a radical transformation driven by breakthroughs in genetic research and targeted therapeutic design. Modern therapies are increasingly personalized and are tailored to address the specific nuances of the patient’s condition.

These shifts are evident as clinicians integrate innovative protocols such as gene therapy alongside established approaches like blood transfusions and bone marrow transplants. Physicians have begun to appreciate the therapeutic potential of a multi-pronged strategy that leverages traditional mechanisms and combines them with emerging pharmacotherapy options. Such evolution in treatment methods is not just enhancing the efficacy of intervention; it is also redefining how practitioners approach and manage the intricacies of Sickle Cell Disease.

The advancements are also reflective of an industry-wide shift towards value-based care, where outcomes are meticulously measured against the long-term benefits conferred by interventions. The market is now oriented towards interventions that are not only effective but also optimized for patient safety and cost efficiency. With burgeoning investment in clinical research and an expanding portfolio of innovative therapies, the treatment paradigm for Sickle Cell Disease is set on a path of continual evolution, bringing forward a future marked by precision and improved patient care.

In-Depth Segmentation Insights in the Sickle Cell Disease Treatment Market

A thorough understanding of the Sickle Cell Disease treatment landscape necessitates careful consideration of various segmentation dimensions that shape market trends and therapeutic approaches. One critical layer involves the segmentation based on treatment type. Within this category, the market is explored through the prism of blood transfusions, bone marrow transplants, and pharmacotherapy. Blood transfusions have been dissected further into acute and chronic interventions, each addressing a distinct facet of patient care. Similarly, bone marrow transplants are categorized to encapsulate allogeneic and autologous procedures, while pharmacotherapy is segmented on the basis of Endari (L-Glutamine) treatment, gene therapy, and hydroxyurea treatment.

Additional segmentation considers the targeted patient age groups where treatment efficacy and risk profiles differ markedly between adult and pediatric populations. This brings a nuanced understanding of the disease’s impact across the lifespan. The method of drug administration, another important segmentation metric, is split into intravenous and oral modalities, reflecting both convenience and safety profiles. Furthermore, disease-specific factors such as Hemoglobin SC Disease (HbSC) versus Sickle Cell Anemia (HbSS) are critically appraised, as these distinctions inform the clinical decision-making process. An exploration of the end user segmentation reveals that clinics, hospitals, and research institutions play significant roles in driving the adoption of these therapies. Within the hospital category, further discrimination is provided between private and public hospitals, which often differ in their access to innovative treatments and resources. Each segmentation parameter offers valuable insight into patient management strategies and highlights areas for future growth, ensuring that every facet of the market is critically analyzed.

Based on Treatment Type, market is studied across Blood Transfusion, Bone Marrow Transplant, and Pharmacotherapy. The Blood Transfusion is further studied across Acute Transfusion and Chronic Transfusion. The Bone Marrow Transplant is further studied across Allogeneic Transplant and Autologous Transplant. The Pharmacotherapy is further studied across Endari (L-Glutamine) Treatment, Gene Therapy, and Hydroxyurea Treatment.

Based on Patient Age Group, market is studied across Adult and Pediatric.

Based on Drug Administration Method, market is studied across Intravenous and Oral.

Based on Disease Type, market is studied across Hemoglobin SC Disease (HbSC) and Sickle Cell Anemia (HbSS).

Based on End User, market is studied across Clinics, Hospitals, and Research Institutions. The Hospitals is further studied across Private Hospitals and Public Hospitals.

Regional Insights Shaping Global Trends in Sickle Cell Disease Treatments

Geographical nuances play a pivotal role in molding the Sickle Cell Disease treatment landscape, as regional differences determine both market dynamics and patient outcomes. Analysis across regions such as the Americas reveals robust investment in clinical research along with well-established healthcare infrastructures, which facilitate the rapid adoption of cutting-edge therapies. In contrast, the Europe, Middle East & Africa region presents a diverse panorama, where variations in healthcare policies and resource allocation lead to differing paces of market penetration. These regions are witnessing accelerated adoption of innovative treatment modalities as local research collaborations expand and regulatory environments evolve.

The Asia-Pacific region, characterized by its fast-growing economies and dynamic healthcare reforms, is increasingly becoming a strategic hotspot for Sickle Cell Disease treatment innovations. With governments and private entities investing heavily in healthcare modernization, there is a significant trend towards incorporating advanced therapeutic techniques that were once limited to more developed regions. Overall, the regional analysis underscores the importance of tailored strategies that consider local market conditions, regulatory requirements, and socio-economic factors. These insights provide a detailed road map for companies and stakeholders looking to carve out a competitive advantage in the global SCD treatment market.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Driving Innovation in Sickle Cell Disease Therapies

The competitive landscape in Sickle Cell Disease treatment is rich with players who are at the forefront of pioneering innovative therapies. Leading organizations such as Akums Drugs and Pharmaceuticals Ltd. and Beam Therapeutics, Inc. are continuously pushing the boundaries of research and development through novel treatment protocols and precision medicine strategies. Companies like Biogen Inc. and Bluebird Bio, Inc. have invested substantially in advanced clinical trials and digital health solutions that facilitate better patient outcomes and streamline treatment delivery formats.

Other notable industry leaders, including Bristol-Myers Squibb Company and CRISPR Therapeutics AG, are setting benchmarks in gene-based therapies. As the market matures, innovative firms such as Editas Medicine, Inc. and Emmaus Medical, Inc. are emerging as significant contributors in the space, while globally recognized entities like F. Hoffmann-La Roche AG and GlycoMimetics, Inc. continue to expand their therapeutic portfolios. Companies like Intellia Therapeutics, Inc. and Medunik USA are critically redefining standard protocols through their investment in breakthrough technologies. Furthermore, global giants such as Novartis AG, Protagonist Therapeutics, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Vertex Pharmaceuticals, Inc., and Vor Biopharma, Inc. provide a broad spectrum of offerings that span from conventional therapies to truly innovative treatment modalities. Their relentless focus on research and clinical excellence is instrumental in fueling the persistent evolution of the Sickle Cell Disease treatment market.

The report delves into recent significant developments in the Sickle Cell Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Akums Drugs and Pharmaceuticals Ltd., Beam Therapeutics, Inc., Biogen Inc., Bluebird Bio, Inc., Bristol-Myers Squibb Company, CRISPR Therapeutics AG, Editas Medicine, Inc., Emmaus Medical, Inc., F. Hoffmann-La Roche AG, GlycoMimetics, Inc., Intellia Therapeutics, Inc., Medunik USA, Novartis AG, Protagonist Therapeutics, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Vertex Pharmaceuticals, Inc., and Vor Biopharma, Inc..

Actionable Recommendations for Strategic Market Advancement

Stakeholders operating in the dynamic landscape of Sickle Cell Disease treatments should consider multi-dimensional strategies to maximize market impact. It is advisable to harness data-driven insights to refine segmentation strategies and create tailored treatment protocols that cater to the unique needs of diverse patient groups. Leaders are encouraged to foster collaborations between research institutions, clinical practitioners, and industry innovators, thereby enabling a more integrated approach to therapy development.

Furthermore, investing in advanced clinical trials and digital solutions can expedite the transition from bench to bedside. Enhancing transparency in clinical outcomes and building robust patient support networks are key factors that will empower both healthcare providers and patients. Stakeholders should also closely monitor regional market trends and regulatory shifts, adapting strategies to leverage local strengths while mitigating potential barriers. A forward-thinking approach that combines technological integration with patient-centric care is essential for sustained market growth.

Charting a Future of Innovation in Sickle Cell Disease Treatment

In summarizing the dynamic landscape of Sickle Cell Disease treatments, it is evident that the integration of traditional therapeutic modalities with innovative interventions has the potential to transform patient outcomes. The segmentation insights, regional trends, and competitive dynamics outlined in this summary underscore a future that is both challenging and filled with opportunity. With strategic investments in research and a commitment to patient-centric care, stakeholders are well-positioned to drive sustainable growth and bring forth a new era of treatment efficacy. As the momentum for innovative healthcare solutions continues to build, the market is poised to deliver substantial advancements that will benefit patients globally.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of sickle cell disease emphasizing the urgent need for effective therapeutic solutions
5.1.1.2. Rising awareness and education efforts about sickle cell disease stimulate demand for effective treatments
5.1.1.3. Government funding and initiatives encouraging research and development in sickle cell disease therapy
5.1.2. Restraints
5.1.2.1. Lengthy and complex regulatory approvals delay the introduction of innovative treatments
5.1.3. Opportunities
5.1.3.1. Implementing telehealth services for routine check-ups and management support
5.1.3.2. Integration of gene therapy developments to enhance long-term treatment outcomes for sickle cell disease
5.1.4. Challenges
5.1.4.1. Side effects and complications associated with sickle cell disease treatment
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Rising need for bone marrow transplants to replace the patient's defective bone marrow with healthy cells
5.2.2. End User: Increasing preference for hospitals due to their comprehensive care for sickle cell disease
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Sickle Cell Disease Treatment Market, by Treatment Type
6.1. Introduction
6.2. Blood Transfusion
6.2.1. Acute Transfusion
6.2.2. Chronic Transfusion
6.3. Bone Marrow Transplant
6.3.1. Allogeneic Transplant
6.3.2. Autologous Transplant
6.4. Pharmacotherapy
6.4.1. Endari (L-Glutamine) Treatment
6.4.2. Gene Therapy
6.4.3. Hydroxyurea Treatment
7. Sickle Cell Disease Treatment Market, by Patient Age Group
7.1. Introduction
7.2. Adult
7.3. Pediatric
8. Sickle Cell Disease Treatment Market, by Drug Administration Method
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Sickle Cell Disease Treatment Market, by Disease Type
9.1. Introduction
9.2. Hemoglobin SC Disease (HbSC)
9.3. Sickle Cell Anemia (HbSS)
10. Sickle Cell Disease Treatment Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Research Institutions
11. Americas Sickle Cell Disease Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Sickle Cell Disease Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Sickle Cell Disease Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Scenario Analysis
14.3.1. Novo Nordisk pioneers sickle cell disease treatment in India
14.3.2. Protagonist Therapeutics files for a patent aimed to treat sickle cell disease
14.3.3. Casgevy and Lyfgenia gene therapies approved for sickle cell disease
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. SICKLE CELL DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. SICKLE CELL DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. SICKLE CELL DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2024 VS 2030 (%)
FIGURE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 17. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 21. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. SICKLE CELL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 27. SICKLE CELL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SICKLE CELL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. SICKLE CELL DISEASE TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ACUTE TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CHRONIC TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ENDARI (L-GLUTAMINE) TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HYDROXYUREA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HEMOGLOBIN SC DISEASE (HBSC), BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY SICKLE CELL ANEMIA (HBSS), BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 65. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 67. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 68. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 71. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 114. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 115. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 118. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. CHINA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 121. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 123. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 124. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 127. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 128. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. INDIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 141. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 142. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 145. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. JAPAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 166. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 193. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 195. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 196. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 197. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 199. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 200. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. THAILAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 202. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 221. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 223. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 224. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 227. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 228. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. DENMARK SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 230. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 232. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 233. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 236. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. EGYPT SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 245. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. FINLAND SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 250. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 251. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 252. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 254. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 255. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. FRANCE SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 259. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 260. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 262. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 263. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 264. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. GERMANY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 277. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 278. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 279. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 280. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 281. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 282. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. ITALY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 294. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DRUG ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANT, 2018-2030 (USD MILLION)
TABLE 305. NORWAY SICKLE CELL DISEASE TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 20

Companies Mentioned

  • Akums Drugs and Pharmaceuticals Ltd.
  • Beam Therapeutics, Inc.
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • F. Hoffmann-La Roche AG
  • GlycoMimetics, Inc.
  • Intellia Therapeutics, Inc.
  • Medunik USA
  • Novartis AG
  • Protagonist Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Vertex Pharmaceuticals, Inc.
  • Vor Biopharma, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.74 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.84 Billion
Compound Annual Growth Rate15.7%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Sickle Cell Disease Treatment - Global Strategic Business Report - Product Image

Sickle Cell Disease Treatment - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report by Treatment Type, End User, and Region 2024-2032 - Product Image

Sickle Cell Disease Treatment Market Report by Treatment Type, End User, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report 2025 - Product Image

Sickle Cell Disease Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Sickle Cell Disease Treatment Market Report and Forecast 2024-2032 - Product Image

Sickle Cell Disease Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Sickle Cell Disease (SCD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Sickle Cell Disease (SCD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 198 Pages
  • Global
From

About the Sickle Cell Drug Market

The Sickle Cell Drug market is a subset of the larger Hematological Drugs market. It is composed of drugs used to treat sickle cell disease, a genetic disorder that affects red blood cells. These drugs are used to reduce the frequency of painful episodes, reduce the risk of organ damage, and improve the quality of life for those affected. Common treatments include hydroxyurea, which helps to reduce the number of sickle cells in the blood, and L-glutamine, which helps to reduce the risk of organ damage. Other treatments include blood transfusions, stem cell transplants, and gene therapy. Companies in the Sickle Cell Drug market include Novartis, GlaxoSmithKline, Pfizer, Sanofi, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.